Chief Financial Officer — Interim, MedTech Scale-Up

The mandate

A pre-IPO review found premature distributor revenue and undocumented development-cost capitalisation, leading the audit committee to request the CFO's resignation. The funding runway is now under nine months while reported growth and margin require reconstruction.

The interim must join inside two weeks for twelve months, covering restatement, growth financing and finance-readiness remediation. A permanent public-company CFO search begins after audited comparatives are issued, with two months planned for overlap.

Handover requires corrected audited financials, at least ₹450 crore of committed runway, a forty-five-day close sustained for three quarters, and a successor who has signed the disclosure, control and forecast baselines.

The interim may reverse unsupported accounting, approve payments below ₹3 crore and negotiate financing inside board parameters. Equity issuance, litigation settlement above ₹5 crore and permanent leadership hires require board consent; product launch and clinical-regulatory choices remain outside finance authority.

IPO timing itself, brand strategy and distributor territory design are expressly excluded. The mandate prepares a credible finance platform and funding option set without promising a listing date.

Why this seat is open

The control review undermined confidence in both the numbers and the executive who certified them. Investors require an independent reset before considering more capital. The board wants an interim who can make difficult accounting corrections, fund the business and give a permanent successor a defensible starting point.

What you will own

• Reconstruct distributor revenue, returns, rebates and cut-off, and propose every required correction to the audit committee.
• Decide the treatment of capitalised development expenditure using project-level technical and recoverability evidence.
• Build a weekly runway model linking placements, consumable pull-through, inventory, collections and regulated launch gates.
• Lead equity and structured-debt workstreams under a board-approved dilution and covenant envelope.
• Install public-company close, disclosure, related-party and controls calendars with named certification owners.
• Recruit temporary technical accounting and controllership capacity within the authorised assignment budget.
• Transfer audited comparatives, financing commitments and control ownership to the permanent CFO through two live cycles.

Candidate qualifications

• Chartered accountant with more than twenty-two years in high-growth, regulated-product or listed-company finance leadership.
• Led a financial restatement or major accounting correction involving revenue recognition or development expenditure.
• Closed at least ₹300 crore of equity, structured debt or crossover funding under constrained runway.
• Deep knowledge of distributor accounting, product gross margin, inventory reserves, foreign subsidiaries and audit governance.
• Experience building disclosure and internal-control discipline suitable for public-market readiness without overselling IPO certainty.
• Demonstrated independence from founders and investors when technical accounting evidence requires an adverse conclusion.

Non-negotiables

• Can assume Mumbai-based finance authority within two weeks.
• No current mandate with prospective investors, auditors or material distributors involved in the company.
• Will make evidence-based restatement recommendations regardless of valuation sensitivity.
• Available exclusively for twelve months and the planned successor handover.

1. 49 words maximum. Confirm your notice position and earliest date for taking statutory finance responsibility in Mumbai.
2. 49 words maximum. What restatement did you lead, and which audit evidence changed the reported result?
3. 49 words maximum. How much runway did you secure under pressure, using which financing structure?